Miniatura

Fitxers

Transcriptional Profile Associated with Clinical Outcomes_Cancers.pdf (7.1 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-09-29

Llicència de publicació

cc by (c) Jimenez, Natalia et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/197342

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/cancers14194757

Resum

Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.

Matèries

Càncer de pròstata, Andrògens

Matèries (anglès)

Prostate cancer, Androgens

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

JIMENEZ, Natalia, REIG TORRAS, Oscar, MARIN AGUILERA, Mercedes, AVERSA, Caterina, FERRER MILEO, Laura, FONT, Albert, RODRIGUEZ VIDA, Alejo, CLIMENT, Miguel ángel, CROS, Sara, CHIRIVELLA, Isabel, DOMENECH, Montserrat, FIGOLS, Mariona, GONZÁLEZ BILLALABEITIA, Enrique, JIMÉNEZ PERALTA, Daniel, RODRIGUEZ CARUNCHIO, Leonardo, GARCIA ESTEVE, Samuel, GARCÍA DE HERRERO, Marta, RIBAL, María josé, PRAT APARICIO, Aleix, MELLADO GONZÁLEZ, Begoña. Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. _Cancers_. 2022. Vol.  14, núm. 19, pàgs. 4757-NA. [consulta: 9 de gener de 2026]. ISSN: 2072-6694. [Disponible a: https://hdl.handle.net/2445/197342]

Exportar metadades

JSON - METS

Compartir registre